Level D· Preclinical EvidenceAnimal Study

Extracellular vesicles from human adipose-derived stem cells relieve pain and inflammation in a rat model of knee osteoarthritis.

Kim WS., Woo CH., Lee KS., Choi YC., Yun YE., Choi JS.

Animal Study on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type: Animal Study
Journal: Stem Cell Res Ther (2026)
Country: England
Reported sample size: —
PMID: 41689136
DOI: 10.1186/s13287-026-04932-7

Abstract (original English)

Inflammatory pain is a hallmark symptom of osteoarthritis (OA), characterized by spontaneous hypersensitivity resulting from tissue damage and chronic inflammation. This study investigates the pain-relieving and cartilage-protective potential of extracellular vesicles (EVs) derived from human adipose-derived stem cells (hASCs) as a cell-free therapeutic approach for OA. hASC-EVs were isolated via multi-filtrations based on tangential flow filtration (TFF) and characterized using transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), dynamic light scattering (DLS), zeta potential measurement, flow cytometry and Liquid chromatography-mass spectrometry (LC-MS/MS)-based proteomic analysis. An in vitro inflammatory OA model was established by treating human osteoarthritic chondrocytes (HC-OA) with interleukin-1β (IL-1β). The expression of inflammation- and pain-related genes was assessed by quantitative PCR (qPCR), and modulation of the Phosphoinositide 3-kinase / Protein kinase B (PI3K/Akt) signaling pathway was analyzed using an antibody array. In vivo therapeutic effects were evaluated in seven-week-old male Wistar rats using a monosodium iodoacetate (MIA)-induced OA model following intra-articular injection of hASC-EVs. Pain behavior was assessed via paw withdrawal latency (PWL), paw withdrawal threshold (PWT), and weight-bearing tests. Cartilage protectio

What this study does not prove

• This study does not prove SVF is an approved treatment or a replacement for standard care.
• This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence

AnimalsHumansExtracellular VesiclesMaleOsteoarthritis, KneeRatsInflammationDisease Models, AnimalRats, WistarChondrocytes

Knee Knee Osteoarthritis Osteoarthritis Chronic Inflammation

View on PubMed DOI

Extracellular vesicles from human adipose-derived stem cells relieve pain and inflammation in a rat model of knee osteoarthritis.

Abstract (original English)

What this study does not prove

Evidence level

Related research

Adipose-Derived Cell Therapies Versus Nonactive Controls for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Clinical Outcomes of Biologic Therapies for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Studies With ≥12-Month Follow-up.

Intra-articular fat grafting for pain relief and functioning improvement in patients with knee osteoarthritis: systematic review.

Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.

Intra-articular adipose-derived cell therapies for knee osteoarthritis: a systematic review of randomized controlled trials.

Total Knee Arthroplasty versus Mesenchymal Stem Cell Therapy for Moderate Knee Osteoarthritis: An Umbrella Analysis of Clinical Outcomes, Quality of Life, and Safety.